Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
28
06
2021
accepted:
05
08
2021
pubmed:
9
9
2021
medline:
27
10
2021
entrez:
8
9
2021
Statut:
ppublish
Résumé
To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89-100%) for any documented infection, 97% (91-100%) for infections with documented symptoms and 89% (43-100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.
Identifiants
pubmed: 34493859
doi: 10.1038/s41591-021-01490-8
pii: 10.1038/s41591-021-01490-8
doi:
Substances chimiques
COVID-19 Vaccines
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1693-1695Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Zambrano, L. D. et al. Update: characteristics of symptomatic women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status—United States, January 22–October 3, 2020. MMWR Morb. Mortal. Wkly. Rep. 69, 1641–1647 (2020).
doi: 10.15585/mmwr.mm6944e3
Wei, S. Q., Bilodeau-Bertrand, M., Liu, S. & Auger, N. The impact of COVID-19 on pregnancy outcomes: a systematic review and meta-analysis. CMAJ 193, E540–E548 (2021).
doi: 10.1503/cmaj.202604
BioNTech SE. Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older https://clinicaltrials.gov/ct2/show/NCT04754594 (2021).
Rubin, R. Pregnant people’s paradox—excluded from vaccine trials despite having a higher risk of COVID-19 complications. JAMA 325, 1027–1028 (2021).
doi: 10.1001/jama.2021.2264
Rasmussen, S. A., Kelley, C. F., Horton, J. P. & Jamieson, D. J. Coronavirus Disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know. Obstet. Gynecol. 137, 408–414 (2021).
doi: 10.1097/AOG.0000000000004290
Goodman, T. Update on WHO Interim Recommendations on COVID-19 Vaccination of Pregnant and Lactating Women https://cdn.who.int/media/docs/default-source/2021-dha-docs/update-on-who-interim-recommendations-on-c-19-vaccination-for-pregnant-and-lactating-women-70-.pdf (2021).
Centers for Disease Control and Prevention. COVID-19 Vaccines While Pregnant or Breastfeeding https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html (2021).
American College of Obstetricians and Gynecologists. COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care (2021).
Shimabukuro, T. T. et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N. Engl. J. Med. 384, 2273–2282 (2021).
doi: 10.1056/NEJMoa2104983
Riley, L. E. & Jamieson, D. J. Inclusion of pregnant and lactating persons in COVID-19 vaccination efforts. Ann. Intern. Med. 174, 701–702 (2021).
doi: 10.7326/M21-0173
Kourtis, A. P., Read, J. S. & Jamieson, D. J. Pregnancy and infection. N. Engl. J. Med. 370, 2211–2218 (2014).
doi: 10.1056/NEJMra1213566
Skjefte, M. et al. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries. Eur. J. Epidemiol. 36, 197–211 (2021).
doi: 10.1007/s10654-021-00728-6
Collier, A.-R. Y. et al. Immunogenicity of COVID-19 mRNA vaccines in pregnant and lactating women. JAMA 325, 2370–2380 (2021).
doi: 10.1001/jama.2021.7563
Dagan, N. et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N. Engl. J. Med. 384, 1412–1423 (2021).
doi: 10.1056/NEJMoa2101765
Barda, N., Dagan, N. & Balicer, R. D. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. Reply. N. Engl. J. Med. 384, 1970 (2021).
pubmed: 33882227
Perl, S. H. et al. SARS-CoV-2-specific antibodies in breast milk after COVID-19 vaccination of breastfeeding women. JAMA 325, 2013–2014 (2021).
doi: 10.1001/jama.2021.5782
Cohen, R. & Rabin, H. Membership in the Health Funds https://www.btl.gov.il/Publications/survey/Documents/seker289/seker_289.pdf (2017).
Centers for Disease Control and Prevention. Certain Medical Conditions and Risk for Severe COVID-19 Illness https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html (2021).
National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines https://www.covid19treatmentguidelines.nih.gov/ (2021).